<img src="https://r2cdn.perplexity.ai/pplx-full-logo-primary-dark%402x.png" style="height:64px;margin-right:32px"/>

# Are there any non-traditional radiation methods that have been used to study resistance patterns and/or overcome resistance?  (By non-traditional, I am referring to techniques such as spatially fractionated radiotherapy, ie GRID, pulsed reduced dose rate radiotherapy, flash radiation therapy, etc.

Non-traditional radiation techniques like spatially fractionated radiotherapy (SFRT/GRID), pulsed reduced dose rate (PDR) radiotherapy, and FLASH radiotherapy have been investigated in preclinical and early clinical studies for their potential to overcome resistance patterns in breast cancer and other tumors, primarily by exploiting unique radiobiological effects such as enhanced immunogenicity, bystander killing, and vascular disruption.[^1][^2][^4]

## Spatially Fractionated Radiotherapy (SFRT/GRID)

SFRT delivers heterogeneous dose patterns with high-dose "peaks" (up to 20-40 Gy) separated by low-dose "valleys," studied extensively for radioresistant tumors including TNBC.

- **Effects on resistance**: In TNBC models resistant to immunotherapy (low CD8+ infiltration, high Tregs/MDSCs), GRID-SFRT increases T-cell infiltration (PD1+/CTLA4+ exhausted T cells), dendritic cells, and cytokines (IFN-γ, IL-10) in both irradiated and unirradiated tumors, promoting abscopal effects via antigen release and bystander killing; it induces necrosis without whole-tumor toxicity, countering immunosuppressive microenvironments.[^1]
- **Differences from conventional RT**: Maintains cancer cell kill via peaks while sparing normal tissue/immune cells in valleys (higher PVDR ~3-5), effective against bulky/resistant tumors where uniform RT fails (e.g., 90% response in sarcoma vs 0-0.5% for EBRT).[^4][^6]
- **Breast cancer data**: Clinical series show 16-93% objective responses in breast cancer metastases, with tumor shrinkage (30-70%) and long-term control in some; mathematical models confirm SFRT enhances cell killing in immune-responsive tumors.[^2][^3]


## Pulsed Reduced Dose Rate (PDR) Radiotherapy

PDR delivers low-dose-rate pulses (e.g., 0.066-0.2 Gy/min) over hours, allowing sublethal damage repair between pulses to preferentially kill resistant cells.

- **Effects on resistance**: Overcomes hypoxia-driven resistance (common in advanced breast cancer) by promoting reoxygenation during pulses; preclinical breast models show superior control of radioresistant clones vs continuous low-dose RT, with reduced fibrosis.[^4]
- **Clinical exploration**: Used in recurrent/resistant breast cancer boosts, with data suggesting better local control in previously irradiated fields; less studied than SFRT but promising for reirradiation.


## FLASH Radiotherapy

FLASH uses ultra-high dose rates (>40 Gy/s) in milliseconds, minimizing normal tissue toxicity while ablating tumors.

- **Effects on resistance**: In resistant breast cancer xenografts, FLASH induces equivalent tumor kill to conventional RT but with 2-3x less lung fibrosis; it modulates resistance via rapid vascular collapse and cGAS-STING activation without adaptive DNA repair, potentially resensitizing immunotherapy-refractory tumors.[^2]
- **Emerging data**: Preclinical TNBC studies show FLASH overcomes DNA repair proficiency (e.g., post-PARPi resistance) better than standard RT; early-phase trials (e.g., breast boosts) report safety and pCR signals, with immune priming for abscopal effects.

These methods reveal resistance patterns like immune exclusion and repair adaptation through biopsy/flow cytometry (e.g., SFRT upregulates checkpoints/MDSCs, suggesting ICI combos), and trials combine them with systemic agents to exploit synergies.[^5][^1][^2]

<div align="center">⁂</div>

[^1]: https://www.cureus.com/abstracts/1435-immune-effects-of-spatially-fractionated-radiation-therapy-in-triple-negative-breast-cancer

[^2]: https://pmc.ncbi.nlm.nih.gov/articles/PMC12055688/

[^3]: https://consultqd.clevelandclinic.org/mathematical-model-provides-further-insight-on-spatially-fractionated-radiotherapy

[^4]: https://pmc.ncbi.nlm.nih.gov/articles/PMC6872856/

[^5]: https://www.sciencedirect.com/science/article/pii/S2405630823001167

[^6]: https://aapm.onlinelibrary.wiley.com/doi/10.1002/acm2.13040

